PRNewsWire
12 Dec 2025, 02:31 UTC · 40w ago
Verdict
Headline takes no side. We score 9926.HK +0.80 — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Akeso received FDA clearance to initiate a global Phase III trial for cadonilimab in gastric cancer.
More negative than 67% of ticker scores this week
Nivolumab is listed as the competitor/control arm and is noted to have limited efficacy in PD-L1 low or negative patients.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 57% of relationship scores this week
[mutual] Akeso's cadonilimab is being tested in a Phase III trial as a treatment for gastric cancer against the current standard of care, which includes nivolumab (produced by Bristol Myers Squibb).
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
22h ago
—
No price for 9926.HK right now — the quote feed didn't answer.
9926.HK chart →
